Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Acquisition of Amolyt Pharma completed

15 July 2024 Acquisition of Amolyt Pharma completed AstraZeneca today announced the successful completion of theacquisition  of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a

Handelsbanken’s interim report for January – June 2024 will be presented Wednesday 17 July

Handelsbanken publishes its interim report for January ­– June 2024, at 07:00 a.m. CET Wednesday, 17 July. The report, slide presentation and Fact Book will be published on handelsbanken.com/ir. Chief Executive Officer, Michael Green, will present the interim report at 09:00 a.m. CET. The presentation will be broadcasted live and available at handelsbanken.com/ir. The presentation will be followed by a short break, after which a Q&A session will follow for analysts, investors and media with Michael Green, Carl Cederschiöld, CFO, and Peter Grabe, Head of Investor Relations. Telephone

Esmaeilzadeh Holding publishes net asset value as of 30 June 2024

As of 30 June 2024, the net asset value for Esmaeilzadeh Holding AB (publ) was SEK 6.64 billion (SEK 7.10 billion as of 31 May 2024), corresponding to a net asset value per share of SEK 8,460 (SEK 9,062 as of 31 May 2024).[1]  For further information, please contact: Mikael Ericson, CEO mikael.ericson@ehab.group For press related enquires, please contact: Michaela Abercrombie Simpson, Head of Communication Phone: +46 736 301 403 The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CEST on 15 July 2024. About

Flexion signs Top Grossing game Zombie Waves

LONDON, 15 July 2024 – Flexion (Nasdaq: FLEXM), the games marketing company has signed an agreement with Fun Formula, a global developer and publisher of cutting-edge casual games, to publish the developer’s successful game Zombie Waves on the alternative app stores. Flexion will distribute the game on the following platforms: Amazon Appstore, Huawei AppGallery, Samsung Galaxy Store, Xiaomi GetApps, DT Hub and ONE store. Zombie Waves is expected to launch on these platforms in September 2024. Flexion is adding an average of 10% to a game’s Google Play revenue by taking it to the

PixelFox Reports Preliminary Revenue and Operating profit for June 2024

Stockholm, July 15, 2024  Period Turnover Operating Result 2024 Turnover 2023 Operating Result 2023 2024June 2,9 MSEK 0,1 MSEK 3,6 MSEK 0,1 MSEK PixelFox has managed to maintain a positive result despite a slight decrease in revenue. The group's efforts and strategies have been crucial in ensuring continued profitability while focusing on developing our core business.For further information, please contact:Robin BäcklundChief Executive OfficerPixelFox AB (publ)ir@wearepixelfox.comPixelFox AB (publ)The business idea of PixelFox AB (

Skanska expands hospital in Astoria, Oregon, USA for USD 74M, about SEK 780M

Skanska has signed a contract with Columbia Memorial Hospital for a hospital expansion project in Astoria, Oregon, USA. The contract is worth USD 74M, about SEK 780M, which will be included in the US order bookings for the third quarter of 2024.The project includes a four story 16,900 square meter (182,000-SF) expansion to the existing hospital to include an expanded emergency department, improved operating rooms, larger patient rooms, space for mechanical equipment, among other enhancements. The expansion will allow Columbia Memorial Hospital to provide new services and the latest medical

Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises

OSLO, NORWAY - July 15, 2024: Microbiome DX company Genetic Analysis AS ("GA" or the "Company") hereby announces that the direct issue which was announced in a press release on the 01.07.2024 has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).GA announced that a direct issue was completed on the 01.07.2024 This provided the Company with approximately NOK 4.97 million by issuance of 6 625 916 new shares, before issue costs. The direct issue has now been registered with the Norwegian Register of Business Enterprises. After this, the Company'

Knox Energy Solutions AS - Annual general meeting completed and notice of reverse share split

(Oslo, 15 July 2024) Knox Energy Solutions AS (Knox, OSE: KNOX) announces that its annual general meeting was held Friday, 12 July 2024, as a virtual meeting, with no physical attendance. The decision was made to do a reverse share split of 100:1 of the shares.All items on the agenda were adopted in accordance with the proposals of the board of directors of Knox. The minutes from the Annual General Meeting will be made available on the company’s website. The decision was made by the required majority to do a reverse share split. The reverse share split was decided as follows: · 100

Bonava is selling project of 89 rental apartments in Germany

Bonava is selling a package of 89 rental apartments in Düsseldorf, Germany, to the investor WOHNBAU GmbH from Bonn. The housing units are expected to be completed and handed over to the customer in the fourth quarter of 2026. Production will start in the third quarter of 2024.– There is huge demand for sustainable rental apartments in Düsseldorf, and it is gratifying that we, despite the current market conditions, can both sell and start this project. There is widespread interest in our rental housing projects, and in the investor segment buyers and sellers are once again starting to do

Interim Report 1 January – 30 June 2024

Good growth in both Business Areas and continued profitability improvement "The companies within AddLife showed strong performance development during the quarter. In Labtech, sales growth recovered as expected and margins remained stable. Sales growth in Medtech was good and margins improved partly driven by restructuring efforts that are now yielding clear results. Cash flow improved significantly and after the end of the quarter, an acquisition was made in line with our updated long-term strategy."Fredrik Dalborg, President and CEO AddLife´s interim report for Q2 2024 is now

Ellos Group withdraws proposal to issue new bonds and to redeem its outstanding super senior bonds prior to maturity – discussion with bondholders continues

NOT FOR DISTRIBUTION IN OR TO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO PUBLISH OR DISTRIBUTE THIS PRESS RELEASEPress release, Borås, 15 July 2024  On 11 June 2024, Ellos Group AB (publ) (“Ellos Group” or the “Company”) announced that its subsidiary Ellos Group Nordic AB (publ) contemplated an issuance of new senior secured bonds and super senior secured bonds (the “New Bonds Issue”) for the purpose of, inter alia,

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

· Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) · Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline · Continuous improvement of acromegaly symptom and quality of life scores vs baseline · Study results reinforce previously reported interim results from ACROINNOVA 2[1] Lund, Sweden, 15 July 2024 — Camurus (NASDAQ STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company’s once-monthly octreotide

Skanska rebuilds 7 Millbank in London, UK, for GBP 105M, about SEK 1.4 billion

Skanska has signed a contract with Baola Properties Limited, c/o Old Park Lane Management, for construction and mechanical and electrical engineering services for the redevelopment of 7 Millbank in London, UK. The contract is worth GBP 105M, about SEK 1.4 billion, which will be included in the order bookings for Europe for the third quarter of 2024.Skanska will lead the construction of a new nine-storey office building with two basement levels. The design and build of approximately 12,100 square meter flexible workspace will include reconstruction of the original historic façade, which has

Orkla reports strong profit improvement

Orkla achieved EBIT (adj.) of NOK 2.0 billion in the second quarter of 2024, up 13% on the same period last year.“Orkla has successfully maintained its positive momentum from the first to the second quarter of the year. The portfolio companies achieved profit growth, a higher return on capital employed and increased cash flow from operations. We are also continuing to ramp up investment in advertising to secure long-term growth and value creation,” says Orkla President and CEO Nils K. Selte. Orkla’s consolidated portfolio companies (including Head Office) grew EBIT (adj.) by 19%, to NOK

Second quarter 2024 result s impacted by higher claims in Norway

This release contains inside information related to Gjensidige Forsikring ASA pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Higher claims for motor and property insurance in Norway had a negative impact on the insurance service result. Adverse development in claims in the first quarter 2024 also contributed to the deterioration of the underlying frequency loss ratio in the second quarter. Ongoing pricing measures have been further strengthened to improve profitability. The insurance

Half-year results 2024

Nordea Bank AbpHalf year financial report15 July 2024 at 7:30 EET Summary of the quarter Continued high-quality income growth. Net interest income grew 4% and net fee and commission income returned to growth, up 6%. Net insurance result and net fair value result were solid, following a strong second quarter last year. Total income improved, up 3%. Inflation and continued significant investments in technology, data and risk management capabilities resulted in a cost increase of 6%, in line with Nordea’s plan. Operating profit held up well, 2% lower compared to a year ago. Return

Smartoptics Group AS (SMOP) – Q2 2024 financial results

Oslo, 15 July 2024 - Smartoptics Group AS (Smartoptics, OSE: SMOP) today reported revenues of USD 13.0 (17.0) million in the second quarter of 2024, and an EBITDA* of USD 1.0 (3.2) million, reflecting continued softness in the market as previously communicated. Anticipating a recovery in the market during the second half of 2024, the company maintains its revenue ambition in the range of USD 100 million by 2025/2026.“Smartoptics is in an ideal position to benefit from the robust and lasting growth trends within optical networks, fueled by the increasing demand for bandwidth. The revenue

A-ROSA enhances entertainment with ‘Young Artists Programme’ on Danube fleet

Award-winning musical talents await A-ROSA guests onboard in ViennaRostock, 15 July 2024 – Guests sailing with A-ROSA on the Danube can now enjoy unique onboard concerts by highly talented students from the Vienna University of Music and Performing Arts (mdw), as part of the river cruise line’s new ‘Young Artists Programme’. Tapping into the musical heritage of the Danube, and Vienna’s reputation as the capital of classical music, guests will be able to enjoy evening performances onboard to showcase the young artists while the ships are docked in the city. The artists cover a diverse

H+H International A/S – Operations have resumed at the Borough Green production facility in the UK

Company announcement No. 562, 2024As informed by H+H International A/S (“H+H”) in company announcement no. 560 of 5 July 2024, production at H+H UK Limited’s Borough Green production facility was ceased due to the unexpected withdrawal of the certification for operating the autoclaves. We have worked extensively to regain the certifications and the autoclaves have now passed the relevant safety tests and are back in operation. Consequently, production can now be ramped-up step-by-step. Until now and during the coming ramp-up phase the expected financial loss (EBIT before special items)

Regulatory approval in China is delayed 4 months

The last and final step in obtaining regulatory approval of the VibroSense Meter ® II in China is delayed approximately four months. The delay is due to that VibroSense's Chinese distributor UMCARE has received many questions on its application, from the Chinese regulatory authority NMPA. According to UMCARE, the NMPA requires an extra careful review because there is no similar instrument in China, which is considered to be an advantage when the product is ready for launch in China. The regulatory approval is now estimated by UMCARE to be obtained at the end of April 2025 compared to their

Spermosens accelerates its US business development activities in collaboration with Scan MedPartners

Spermosens is accelerating its business development activities and has entered into an agreement with US based Scan MedPartners as its business development advisor to identify and attract potential strategic and commercial partners in North America with a special focus on the US market.As previously communicated, Spermosens is focused on securing licensing and co-development partners for its first of kind automated sperm diagnostic device JUNO-Checked. In line with this effort, Spermosens today announces a collaboration with Scan MedPartners, thereby significantly strengthening the company'

Tietoevry Care wins an openEHR-based platform procurement for a large Swedish University hospital

Tietoevry Care has won a prestigious procurement to implement an openEHR-based solution, the Lifecare Open Platform, at a large University hospital in Sweden. The new solution enables more efficient patient-centered care with less administration. The implementation marks an important step for care providers within the capital region that want to take ownership of and make available all clinical data.For big and small ideas in healthcare Based on open standards for electronic health records, openEHR, the Lifecare Open Platform complements existing healthcare systems by compiling

There are no items matching the current filter
There are no more items matching the current filter
Back to top